December 15th, 2015

Bill Gates Dedicates $30M into Alzheimer's Treatments

Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential

HENDERSON, NV / ACCESSWIRE / July 23, 2018 / Along with several other philanthropists, Bill Gates recently announced he is putting $30 million into the Diagnostics Accelerator, a "venture philanthropy" fund to develop early diagnostic procedures and bring them to market quickly.

One small Alzheimer related biotech firm on our radar is Endonovo Therapeutics, Inc. (ENDV). ENDV could be just one little push from a massive inflection point. This company has traded well over 300% higher in the last year. There was a massive rush into ENDV last October, and smart, risk tolerant investors could take advantage of this opportunity.

Gates hopes to get Alzheimer's patients diagnosed earlier.

Alzheimer's is a brain disease that affects memory, motor functions, and eventually, a person's ability to function properly in daily life. If you live to 85 - which is not uncommon in the modern world - you have a one-third chance of developing the disease, according to the Alzheimer's Association. As the US population ages, the disease is expected to affect 13.8 million by 2050.

At the beginning of the year, several companies started giving up on treating the disease. However, many still remain in the space, and could benefit from Gates' crusade against the disease.

Endonovo Therapeutics, Inc. (ENDV)

Market cap: $11.649 million; current share price: $0.0332

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, recently announced that the first patient has been enrolled in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company's senior secured Series C Preferred Stock financing.

"The initiation of this study represents a significant milestone for Endonovo," said Endonovo CEO, Alan Collier. "We believe our technology, whose proven mechanism of action is the suppression of inflammation, has the potential to change the treatment of central nervous system disorders where neuroinflammation propagates injury such as ischemic stroke, Alzheimer's disease and Multiple Sclerosis."

Biogen, Inc. (NASDAQ: BIIB)

Market cap: $75.56 billion; current share price: $358.11

Biogen Inc. seems to be one step closer to figuring out Alzheimer's after it posted promising results from its mid-stage drug trial July 6.

The pharma company's BAN2401 showed to significantly delay the mental deterioration of patients afflicted with the disease by targeting amyloid plaque buildup on the brain, which is thought to be a possible cause of Alzheimer's.

Biogen's test results also boded well for the large-cap pharma sector that has struggled to develop new, exciting treatments that generate investor interest. Smaller biotech firms have been driving innovation in the industry and have reaped the rewards of their successes. Biotech companies in 2018 are being acquired at the highest rate the industry has seen in the past 12 years.

Roche Holding (RHHBY)

Market cap: $75.56 billion; current share price: $28.91

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible. They are still working on a treatment for Alzheimer’s.

The Eli Lilly Company (LLY)

Market cap: $91.27 billion; current share price: $89.43

Lilly has been a global leader in the fight against Alzheimer's for nearly 30 years. Today, Lilly has molecules and diagnostics in various stages of clinical development, including seven investigational compounds to treat Alzheimer's and two diagnostics to help better diagnose it.

Conclusion

While several giants remain in the Alzheimer's game, smaller upstarts like ENDV could benefit from Gates' new fund.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixty four thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.